CurifyLabs, a Finland-based company automating non-sterile compounding of personalized medicines, has raised $14M in Series A funding co-led by Sandwater and HealthCap. Its Compounding System Solution combines GMP-manufactured excipient bases, PharmaPrinter robotics, quality control, and compliance software to deliver up to 9x faster compounding than manual processes. The capital will expand US operations, strengthen supply chain, and advance R&D.
Pharmacy Automation Gains Momentum
The timing aligns with regulatory pressure and labor shortages pushing compounding pharmacies toward automation. Aprecia Pharmaceuticals raised $176M across 11 rounds for large-scale 3D-printed drug manufacturing, while Triastek secured over $103M for centralized production. CurifyLabs differentiates by targeting point-of-care pharmacy compounding with an end-to-end system built for USP <795> and <800> compliance.
Manual Dosing Risks Drive Demand
Traditional compounding and tablet splitting introduce significant variability. A Mayo Clinic study published in Pharmaceutics found manually split quarters varied from 25% to 143% of the labeled dose for low-dose metoprolol, while 3D-printed tablets achieved 90–103% mean API content with standard deviation under 5%. Pharmacies compound thousands of doses daily, often for pediatric, geriatric, and oncology patients requiring precise personalization.
End-to-End System Targets Pharmacy Workflow
CurifyLabs built the only full Compounding System Solution integrating hardware, CuraBlend excipient bases, validated formulation library, digital batch records, and in-process QC. Unlike FABRX's research-focused standalone printers or Multiply Labs' industrial-scale systems for cell therapies, CurifyLabs delivers a pharmacy-counter-ready platform with ISO 13485 certification and 21 CFR Part 11 compliance.
As Morten E. Iversen of Sandwater noted:
"CurifyLabs has built something rare — technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on."
Nordic Investors Back US Expansion
Sandwater and HealthCap led the round, with participation from Tesi and Lifeline Ventures plus US customers and employees. HealthCap's track record backing 136 life sciences companies signals strong sector conviction in decentralized manufacturing. The investment follows CurifyLabs' prior $2M commitment to its Jacksonville, Florida headquarters.
Compounding Market Expands Rapidly
The 3D printed drugs market stands at $435.8M in 2026 and is projected to reach $1.1B by 2036. The global compounding pharmacy market is valued at $14.04B in 2026, growing to $29.2B by 2036. Key drivers include aging populations, chronic disease prevalence, and supply chain resilience needs after the pandemic.
Leadership with Deep Domain Expertise
Co-founders Charlotta Topelius (CEO) and Niklas Sandler (CTO) bring pharmacist perspectives and over 100 peer-reviewed publications from Sandler in pharmaceutical technology. The team leads the €5.6M EU-funded RoboPharma project focused on AI- and robotics-driven decentralized manufacturing.
US Rollout Accelerates
With deployments across 21 US states and 15 countries serving 30,000 patients monthly, CurifyLabs plans to scale US operations, bolster supply chain infrastructure, and expand R&D following the round.